Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Visvanathan K et al. - In a study to update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction, it was determined that in women at increased risk for BC, tamoxifen (20 mg/d for 5 yrs) may be offered to reduce risk of invasive ER-positive BC, with benefits for at least 10 yrs. In postmenopausal women, raloxifene (60 mg/d for 5 yrs) may also be considered. Use of aromatase inhibitors, fenretinide, or other selective estrogen receptor modulators to lower BC risk is not recommended outside of a clinical trial. Discussion of risks and benefits of preventive agents is critical to pt decision making.

Methods

Results

Related Articles

Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3N-EPIC Prospective Cohort Study
American Journal of Epidemiology, 10/22/09    Relevance Score: 90%

Breast cancer screening can lead to unnecessary treatment
Internet Source, 11/12/09    Relevance Score: 89%

Rethinking Screening for Breast Cancer and Prostate Cancer
JAMA, 10/23/09    Relevance Score: 89%

Physical therapists play integral role in prevention, risk reduction, and treatment of lymphedema
EurekAlert, 10/16/09    Relevance Score: 89%

The impact of changes in hormone therapy on breast cancer incidence in the US population
Cancer Causes and Control, 10/07/09    Relevance Score: 89%

Today in Pharmacology/Therapy...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address